Table 6.
Results: subgroup analyses
| Combination therapy v no treatment | Combination therapy v monotherapy | |||||
| Subgroup | Marginal cost (£) | Marginal effectiveness (QALY) | Marginal cost effectiveness (£/QALY) | Marginal cost (£) | Marginal effectiveness (QALY) | Marginal cost effectiveness (£/QALY) |
| Men | 4701 | 1.11 | 4247 | 2603 | 0.76 | 3429 |
| Women | 4289 | 1.47 | 2913 | 2556 | 0.73 | 3514 |
| Genotype 1 | 6330 | 0.69 | 9170 | 4327 | 0.50 | 8626 |
| Genotype 2 or 3 | 2848 | 1.73 | 1646 | 861 | 0.99 | 872 |
| Age 40 y or less | 4398 | 1.50 | 2942 | 2511 | 0.79 | 3197 |
| Age 41–50 y | 4868 | 1.00 | 4855 | 2722 | 0.73 | 3705 |
| Age over 50 y | 4873 | 0.76 | 6402 | 2901 | 0.58 | 5016 |
| Viral load >2 million counts | 4796 | 1.12 | 4299 | 2772 | 0.75 | 3676 |
| Viral load ≤2 million counts | 4620 | 1.27 | 3627 | 2688 | 0.56 | 4792 |
| Mild hepatitis | 5507 | 0.80 | 6925 | 3083 | 0.52 | 5900 |
| Moderate hepatitis | 4161 | 1.44 | 2897 | 2356 | 0.86 | 2735 |
QALY, quality adjusted life year.